key: cord-0698451-lq3bztvl
authors: Dale, Ariella P.; Hudson, Matthew; Cullen, Theresa; Ellingson, Katherine; Davis, Kat; Armenta, Darunee; Friebus, Heather; Currie, Chase; Bhattarai, Rachana; Brady, Shane; Komatsu, Ken; Stone, Nimalie; Uyeki, Timothy; Slifka, Kara Jacobs; Perez-Velez, Carlos; Keaton, Amelia
title: Administration of Bamlanivimab to Skilled Nursing Facility Residents during a COVID-19 Outbreak, January-February 2021, Arizona
date: 2021-05-04
journal: J Am Med Dir Assoc
DOI: 10.1016/j.jamda.2021.04.023
sha: 27656a5134e75f1bfbdf0d8b7a51b1b8d6c279ed
doc_id: 698451
cord_uid: lq3bztvl

nan

Outbreak, January-February 2021, Arizona 2 In November 2020, the Food and Drug Administration (FDA) issued an emergency use 3 authorization (EUA) for bamlanivimab, a monoclonal antibody (mAb), for treatment of mild-moderate 4 COVID-19 in non-hospitalized individuals at high-risk for severe disease. 1 Since that time, several other 5 mAb therapies, either alone or in combination, have also been issued EUA for use of the treatment of Our team conducted interviews with facility staff and local public health department personnel to 18 understand their process for obtaining and administering bamlanivimab.

Bamlanivimab was offered to any resident with mild-to-moderate COVID-19 within 10 days of 20 symptom onset and who was at high risk for severe disease as outlined in the FDA EUA for 

COVID-19 News Release: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19

US Food & Drug Administration website

Accessed February 14, 2021. 66 2. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for

US Food & Drug Administration website